Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia

Alexandre Persu, Piotr Dobrowolski, Heather L. Gornik, Jeffrey W. Olin, David Adlam, Michel Azizi, Pierre Boutouyrie, Rosa Maria Bruno, Marion Boulanger, Jean Baptiste Demoulin, Santhi K. Ganesh, Tomasz J. Guzik, Magdalena Januszewicz, Jason C. Kovacic, Mariusz Kruk, Peter De Leeuw, Bart L. Loeys, Marco Pappaccogli, Melanie H.A.M. Perik, Emmanuel TouzéPatricia Van Der Niepen, Daan J.L. Van Twist, Ewa Warchoł-Celińska, Aleksander Prejbisz, Andrzej Januszewicz

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)


Fibromuscular dysplasia (FMD) is a non-atherosclerotic vascular disease that may involve medium-sized muscular arteries throughout the body. The majority of FMD patients are women. Although a variety of genetic, mechanical, and hormonal factors play a role in the pathogenesis of FMD, overall, its cause remains poorly understood. It is probable that the pathogenesis of FMD is linked to a combination of genetic and environmental factors. Extensive studies have correlated the arterial lesions of FMD to histopathological findings of arterial fibrosis, cellular hyperplasia, and distortion of the abnormal architecture of the arterial wall. More recently, the vascular phenotype of lesions associated with FMD has been expanded to include arterial aneurysms, dissections, and tortuosity. However, in the absence of a string-of-beads or focal stenosis, these lesions do not suffice to establish the diagnosis. While FMD most commonly involves renal and cerebrovascular arteries, involvement of most arteries throughout the body has been reported. Increasing evidence highlights that FMD is a systemic arterial disease and that subclinical alterations can be found in non-affected arterial segments. Recent significant progress in FMD-related research has led to improve our understanding of the disease's clinical manifestations, natural history, epidemiology, and genetics. Ongoing work continues to focus on FMD genetics and proteomics, physiological effects of FMD on cardiovascular structure and function, and novel imaging modalities and blood-based biomarkers that can be used to identify subclinical FMD. It is also hoped that the next decade will bring the development of multi-centred and potentially international clinical trials to provide comparative effectiveness data to inform the optimal management of patients with FMD.

Original languageEnglish
Pages (from-to)65-83
Number of pages19
JournalCardiovascular Research
Issue number1
Publication statusPublished - 1 Jan 2022
Externally publishedYes


Dive into the research topics of 'Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia'. Together they form a unique fingerprint.

Cite this